BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells $3,308,855.85 in Stock

Key Points

• Chan Henry Lee, Senior Vice President of BeOne Medicines, sold 11,013 shares for approximately $3.31 million at an average price of $300.45, with the transaction disclosed to the SEC.
• BeOne Medicines reported a Q2 EPS of $0.84, surpassing analysts' expectations by $0.36, and had a revenue of $1.32 billion, exceeding estimates of $1.24 billion.
• Multiple analysts have upgraded BeOne Medicines, with Morgan Stanley increasing their price target from $313 to $330 and Royal Bank of Canada raising their target from $349 to $364.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 11,013 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $300.45, for a total transaction of $3,308,855.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, July 30th, Chan Henry Lee sold 920 shares of BeOne Medicines stock. The stock was sold at an average price of $304.60, for a total transaction of $280,232.00.
• On Monday, June 16th, Chan Henry Lee sold 422 shares of BeOne Medicines stock. The stock was sold at an average price of $266.50, for a total transaction of $112,463.00.
• On Friday, June 6th, Chan Henry Lee sold 700 shares of BeOne Medicines stock. The stock was sold at an average price of $256.11, for a total transaction of $179,277.00.

BeOne Medicines Stock Performance

ONC stock traded up $11.67 during mid-day trading on Friday, reaching $321.36. The company had a trading volume of 448,792 shares, compared to its average volume of 437,341. BeOne Medicines Ltd. - Sponsored ADR has a fifty-two week low of $170.99 and a fifty-two week high of $321.69. The company has a market cap of $35.22 billion, a P/E ratio of -185.76 and a beta of 0.27. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72. The company has a fifty day moving average of $274.62.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The firm had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.24 billion. As a group, analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ONC shares. Morgan Stanley boosted their price objective on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a report on Friday, June 27th. Royal Bank Of Canada upped their price target on shares of BeOne Medicines from $349.00 to $364.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. TD Securities reaffirmed a "buy" rating and issued a $334.00 price target on shares of BeOne Medicines in a report on Thursday, April 24th. Wall Street Zen raised shares of BeOne Medicines from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Guggenheim lifted their price target on BeOne Medicines from $350.00 to $365.00 and gave the company a "buy" rating in a research report on Thursday, August 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $330.89.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC purchased a new position in BeOne Medicines during the 2nd quarter valued at about $59,000. Aaron Wealth Advisors LLC purchased a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $200,000. Farther Finance Advisors LLC acquired a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $39,000. Avanza Fonder AB acquired a new position in shares of BeOne Medicines during the 2nd quarter worth approximately $199,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in BeOne Medicines in the 2nd quarter valued at approximately $3,491,000. 48.55% of the stock is owned by hedge funds and other institutional investors.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.